CliffBio
small molecule

NOURESS

CYSTEINE HYDROCHLORIDE

Loss of exclusivityMarch 2039latest FDA-listed patent expiry
CompanyBaxter Healthcare Corp →See this company's full patent-cliff portfolio

Drug detail

Brand nameNOURESS
Active ingredientCYSTEINE HYDROCHLORIDE
Strength500MG/10ML (50MG/ML)
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalDecember 2019
Marketing statusDISCN

Listed patents

PatentExpiresType
10702490March 2039product
11045438March 2039product
10493051March 2039product
10543186March 2039use U-2722
11510941March 2039product
10905714January 2039product
11642370January 2039product
10918662January 2039product
12569514January 2039product
11648262January 2039product
11679125January 2039product
10653719January 2039product
10912795January 2039product
10933089January 2039product
10905713January 2039product
11684636January 2039product
10478453January 2039product
10583155January 2039product
11510942January 2039product
11826383January 2039product

More from Baxter Healthcare Corp

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

Not found